A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 (clinicaltrials.gov) - Sep 10, 2026 - P4 | N=35 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Dec 2026 ➔ Jan 2028 | Trial primary completion date: Dec 2026 ➔ Jan 2028
Trial completion date • Trial primary completion date • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|